MedTrace Logo

Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan

NCT00276445 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2006-11-07

No results posted yet for this study

Summary

Intravenous- injection of beta-1,3-glucan in human is known to induce T helper type 1 response, while oral uptake did not. It was examined whether superfine dispersed beta-1,3-glucan (SDG) contrived to absorbed by intestinal mucosa would alleviate allergic symptoms by per-oral ingestion

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

beta-1,3-glucan

Sponsors & Collaborators

  • Kyoto Prefectural University of Medicine

    collaborator OTHER

  • Meiji University of Oriental Medicine

    lead OTHER

Principal Investigators

  • Jun Yamada, M.D. Ph.D. · Meiji University of Oriental Medicine

  • Junji Hamuro, Ph.D. · Kyoto Prefectural University of Medicine

  • Shigeru Kinoshita, M.D. Ph.D. · Kyoto Prefectural University of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Completion
2004-06-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276445 on ClinicalTrials.gov